| | This Month in AJKD
|
Refers to article:
|
|
Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial
, 25 July 2008
Hiromichi Suzuki, Yoshihiko Kanno, Soichi Sugahara, Naofumi Ikeda, Junko Shoda, Tsuneo Takenaka, Tsutomu Inoue, Ryuichiro Araki
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 501-506)
Abstract |
Full Text |
Full-Text PDF (158 KB)
|
Improving Outcomes in Hemodialysis Patients: The Need for Well-Designed Clinical Trials
Robert D. Toto
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 400-402)
Full Text |
Full-Text PDF (58 KB)
|
Urinary Neutrophil Gelatinase-Associated Lipocalin and Acute Kidney Injury After Cardiac Surgery
, 24 July 2008
Gebhard Wagener, Gina Gubitosa, Shuang Wang, Niels Borregaard, Mihwa Kim, H. Thomas Lee
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 425-433)
Abstract |
Full Text |
Full-Text PDF (288 KB)
|
Neutrophil Gelatinase–Associated Lipocalin (NGAL) as a Marker of Kidney Damage
, 03 April 2008
Davide Bolignano, Valentina Donato, Giuseppe Coppolino, Susanna Campo, Antoine Buemi, Antonio Lacquaniti, Michele Buemi
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 595-605)
Abstract |
Full Text |
Full-Text PDF (1246 KB)
|
NGAL in Acute Kidney Injury: From Serendipity to Utility
Prasad Devarajan
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 395-399)
Full Text |
Full-Text PDF (79 KB)
|
Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
, 04 August 2008
Mahboob Rahman, Charles Baimbridge, Barry R. Davis, Joshua Barzilay, Jan N. Basile, Mario A. Henriquez, Anne Huml, Nelson Kopyt, Gail T. Louis, Sara L. Pressel, Clive Rosendorff, Sithiporn Sastrasinh, Carol Stanford, ALLHAT Collaborative Research Group
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 412-424)
Abstract |
Full Text |
Full-Text PDF (426 KB)
|
Add-Ons
|
Statins for Slowing Kidney Disease Progression: An as yet Unproven Indication
Marcello Tonelli
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 391-394)
Full Text |
Full-Text PDF (68 KB)
|
The Effect of On-line High-flux Hemofiltration Versus Low-flux Hemodialysis on Mortality in Chronic Kidney Failure: A Small Randomized Controlled Trial
, 10 July 2008
Antonio Santoro, Elena Mancini, Roberto Bolzani, Rolando Boggi, Leonardo Cagnoli, Angelo Francioso, Maurizio Fusaroli, Valter Piazza, Renato Rapanà, Giovanni F.M. Strippoli
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 507-518)
Abstract |
Full Text |
Full-Text PDF (348 KB)
|
“Artificial” Hemodialysis Versus “Natural” Hemofiltration
Thomas A. Depner
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 403-406)
Full Text |
Full-Text PDF (66 KB)
|
Outcomes of Kidney Transplantation From Older Living Donors to Older Recipients
, 25 July 2008
Jagbir Gill, Suphamai Bunnapradist, Gabriel M. Danovitch, David Gjertson, John S. Gill, Michael Cecka
American Journal of Kidney Diseases
September 2008 (Vol. 52, Issue 3, Pages 541-552)
Abstract |
Full Text |
Full-Text PDF (503 KB)
|
ARBs and Cardiovascular Events in Hemodialysis  See Suzuki et al, pages 501-506; and Toto, pages 400-402. Cardiovascular disease (CVD) is the leading cause of mortality in patients on hemodialysis, but the effects of treatment with angiotensin receptor blockers (ARBs) in these patients is not known. In this issue, Suzuki et al perform an open-label randomized trial among patients at 5 centers aged 30 to 80 years receiving hemodialysis 2 to 3 times weekly for 1 to 5 years (n = 180) to compare ARB treatment versus treatment without ARBs. Overall, there were 93 (52%) fatal and nonfatal CVD events (primary end points) and 63 (35%) fatal events (secondary endpoints). There were significantly fewer primary endpoints in the ARB group, but the difference in all cause mortality was not significant. An editorial by Dr Toto reviews the difficulty in interpreting this “positive” clinical trial. NGAL in Acute Kidney Injury See Wagener et al, pages 425-433; Bolignano et al, pages 595-605; and Devarajan, pages 395-399. A few recent studies have shown that urinary neutrophil gelatinase–associated lipocalin (NGAL) could be a useful biomarker to detect kidney injury. In this issue, Wagener et al measured pre and postoperative (0, 3, 18, and 24 hours post surgery) NGAL levels in a large, heterogeneous cohort of adult cardiac surgical patients from a single center (n = 426). The patients that developed acute kidney injury (AKI), defined as a rise in serum creatinine concentration, had significantly greater urinary NGAL values at the end of surgery and 3 hours later, but the area under the receiver operator curve was only 0.603 (95% CI; 0.533 to 0.674; P = 0.003), indicating poor predictive ability. However, the early urinary NGAL values correlated better with cardiopulmonary bypass and aortic cross-clamp times than did changes in serum creatinine, suggesting that urinary NGAL may reflect kidney injury during cardiac surgery better than changes in serum creatinine. A review by Bolignano et al and an editorial by Dr Devarajan further elucidate the potential benefits and shortcomings of NGAL as a biomarker for predicting AKI. Statins to Slow the Progression of Kidney Disease See Rahman et al, pages 412-424; and Tonelli, pages 391-394. While dyslipidemia is common in patients with CKD, the effect of statin therapy on kidney disease progression is unclear. In this issue, Rahman et al performed a post-hoc analysis of 10,060 moderately hypercholesterolemic and hypertensive patients enrolled in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, Lipid Lowering Trial (ALLHAT-LLT), a prospective randomized trial that compared pravastatin therapy versus usual care. They found that after 6 years, total cholesterol levels decreased in both the pravastatin (−20.7%) and usual care (−11.2%) groups with no significant differences in rates of end-stage renal disease, composite end points of end-stage renal disease and 50% or 25% decrease in estimated glomerular filtration rate (eGFR), or rate of change in eGFR, with findings consistent across eGFR strata. The authors conclude that the study suggest statins do not slow the progression of kidney disease. An editorial by Dr Tonelli asserts that closer scrutiny of the design and conduct of the ALLHAT trial (such as drop-in and drop-out effects) may explain the negative result. High-Flux Hemofiltration Versus Low-Flux Hemodialysis See Santoro et al, pages 507-518; and Depner, pages 403-406. Santoro et al compare on-line high-flux hemofiltration (HF) with ultrapure low-flux hemodialysis (HD) in a small, centrally randomized trial (20 centers, 32 patients). They found that there was significant improvement in survival with HF compared with HD (78% versus 57%, respectively) at 3 years of follow up after allowing for the effects of age (P = 0.05). They also observed increased end of treatment Kt/V and decreased body mass index in the HD group, while the HF group showed decreased β2-microglobulin levels, length of hospital stay, and trends of intradialytic acute hypotension. An editorial by Dr Depner reviews differences between filtration and dialysis and calls for a larger study. Older Living Donors and Older Transplant Recipients See Gill et al, pages 541-552. Increasing numbers of elderly patients are on waiting lists for kidney transplants. In this issue, Gill et al used data from OPTN/UNOS from 1996 to 2004 to compare outcomes among 23,754 transplant recipients older than 60 years who received transplants from older living donors (OLD) with those from other sources. They found that transplantations from older living donors were associated with inferior 3-year graft survival rates (85.7%) than younger living donors (YLD) and had superior graft survival compared with standard criteria (SCD) and extended criteria (ECD) deceased donor options. Based on these results, the authors suggest that older living donors be considered as a transplant option for elderly patients. PII: S0272-6386(08)01131-1 doi:10.1053/S0272-6386(08)01131-1 | |
|
FULL TEXT01131-1/journalimage?img=PIIS0272638608011311.gr1.lrg.gif&fig=&kwhquery=&issn=0272-6386&ishighres=false&allhighres=false&free=yes','journalimage');)
01131-1/journalimage?img=PIIS0272638608011311.gr2.lrg.gif&fig=&kwhquery=&issn=0272-6386&ishighres=false&allhighres=false&free=yes','journalimage');)
01131-1/journalimage?img=PIIS0272638608011311.gr3.lrg.gif&fig=&kwhquery=&issn=0272-6386&ishighres=false&allhighres=false&free=yes','journalimage');)
01131-1/journalimage?img=PIIS0272638608011311.gr4.lrg.gif&fig=&kwhquery=&issn=0272-6386&ishighres=false&allhighres=false&free=yes','journalimage');)
01131-1/journalimage?img=PIIS0272638608011311.gr5.lrg.gif&fig=&kwhquery=&issn=0272-6386&ishighres=false&allhighres=false&free=yes','journalimage');)